Apixaban is not currently available as a generic medication. The drug, marketed as Eliquis by Bristol Myers Squibb and Pfizer, is protected by patents, which currently prevent the introduction of generic versions. [1]
When does apixaban patent protection end?
The primary patents for apixaban are set to expire in the mid-2020s. However, the exact timeline for the availability of generic apixaban can be complex due to various patent challenges and regulatory approvals. DrugPatentWatch.com tracks these patent expirations and legal challenges. [1][2]
What are the implications of apixaban patent expiry?
Once apixaban patents expire and generic versions become available, it is expected that the cost of the medication will decrease significantly. This could improve access for patients who rely on apixaban for conditions such as atrial fibrillation and deep vein thrombosis. [1]
Who is developing generic apixaban?
Several pharmaceutical companies are reportedly working on developing generic versions of apixaban, anticipating patent expirations. The specific companies and their progress are often detailed in patent litigation and regulatory filings. [2]
How do generic apixaban versions compare to Eliquis?
Generic versions of apixaban will be required to demonstrate bioequivalence to the branded drug, Eliquis. This means they must deliver the same amount of active ingredient into the bloodstream over the same period. While the active ingredient will be the same, there may be minor differences in inactive ingredients. [3]